Characterisation of enterocolitis in the piroxicam-accelerated interleukin-10 knock out mouse — A model mimicking inflammatory bowel disease

• Published in: Journal of Crohn's and colitis Vol. 8; no. 2; pp. 147 - 160
• Main Authors: Holgersen, Kristine, Kvist, Peter Helding, Markholst, Helle, Hansen, Axel Kornerup, Holm, Thomas Lindebo
• Format: Journal Article
• Language: English
• Published: England Elsevier B.V 01.02.2014
• Subjects: Ampicillin - therapeutic use; Animals; Anti-Bacterial Agents - therapeutic use; Antibodies, Monoclonal - therapeutic use; Colon - pathology; Crohn's disease; Cytokines - metabolism; Diarrhea - etiology; Disease Models, Animal; Enterocolitis - chemically induced; Enterocolitis - complications; Enterocolitis - drug therapy; Enterocolitis - pathology; Female; Granuloma - pathology; Hyperplasia - pathology; Ileum - pathology; Immunologic Factors - therapeutic use; Inflammatory bowel disease; Inflammatory Bowel Diseases - pathology; Interleukin-10 - genetics; Interleukin-10 knock out mouse; Intestinal Mucosa - pathology; Killer Cells, Natural; Leukocyte Count; Mice, Inbred C57BL; Mice, Knockout; Monocytes; Neutrophils; Piroxicam; Weight Loss; Inflammatory bowel disease; IL-10 k.o; Piroxicam; PAC; Interleukin-10 knock out mouse; NSAID; Crohn's disease; COX; Meics; WT; mAb; interleukin-10 knock out; cyclooxygenase; piroxicam-accelerated colitis; non-steroidal anti-inflammatory drug; wild type; murine endoscopic index of colitis severity; monoclonal antibody
• ISSN: 1873-9946; 1876-4479
• DOI: 10.1016/j.crohns.2013.08.002

In inflammatory bowel disease a defective mucosal barrier, a dysregulated immune response and an excessive reactivity against the gut microbiota are assumed to cause a breakdown of the intestinal homeostasis and lead to chronic inflammation. Piroxicam treatment is a method for induction of colitis in IL-10 k.o. mice, which integrates a dysfunction of both the intestinal barrier and the immune system. However, the translational value of this model has not been thoroughly clarified. To characterise the piroxicam-accelerated colitis (PAC) IL-10 k.o. model with respect to clinical features, pathogenic mechanisms and its ability to respond to existing therapies. The PAC IL-10k.o. model was established on a C57BL/6J background and the clinical manifestations, immunological mechanisms and efficacy of ampicillin and anti-IL-12/23p40 treatment were assessed. The PAC IL-10 k.o. mice developed weight loss and diarrhoea, and colonoscopy revealed a thickened granulomatous mucosa. Histological evaluation of ileum and colon showed Crohn's disease-like changes with pronounced hyperplasia and focal transmural inflammation. Ileitis was also observed in piroxicam treated wild type mice. The total number of neutrophils, monocytes and natural killer cells was elevated in the blood compared to IL-10 k.o. and wild type mice, indicating a role of the innate immune system in the pathogenesis. These findings were supported by analyses of the intestinal cytokine profile. Ampicillin and anti-IL-12/23p40 treatment significantly suppressed disease in the model. The PAC IL-10 k.o. model resembles several features of Crohn's disease and could be a useful in vivo model in preclinical research.